Zogenix, Inc. (NASDAQ: ZGNX) is having an incredibly rough start to the trading session in the pre-market hours this morning, and for good reason. The comapny announced a rejection from the FDA, upsetting investors and sending the stock tumbling. Today, we’ll talk about: The rejection; what we’re seeing from ZGNX stock as a result; and … Read more
Zogenix, Inc. (NASDAQ: ZGNX) is flying in the pre-market hours this morning, and for good reason. The company announced positive results from a pivotal clinical trial. Of course, the news led to excitement among investors who are sending the stock screaming for the top. Today, we’ll talk about: The clinical results; what we’re seeing from … Read more
Zogenix, Inc. (NASDAQ: ZGNX) is having yet another relatively strong day in the market today, and for good reason. Recently, the company released positive Phase 3 clinical data surrounding a treatment they have been working on for Dravet syndrome; a rare, yet severe form of epilepsy. While the data was first released last week, messages … Read more
Zogenix, Inc. (NASDAQ: ZGNX) is having an overwhelmingly strong start to the trading session in the pre-market this morning, and for good reason. The company reported overwhelmingly positive clinical data surrounding its epilepsy drug. Of course, this led to excitement among investors, sending the stock toward the top. As is almost always the case, our … Read more
Celgene Corporation Climbs After Acquisition Celgene Corporation (NASDAQ: CELG) Celgene Corporation stock is up in a big way today after the company announced after hours Tuesday that it had acquired Receptos (RCPT). The deal was valued at roughly $7.2 billion or $232 per share in cash. The goal of the acquisition of for CELG to … Read more
Zogenix (ZGNX) Produces A Loss For Q4 And Sells Zohydro Zogenix (ZGNX) recently announced that in Q4, the company lost more than $20 million. Also Zogenix (ZGNX) announced that it would be selling its Zohydro ER business to Pernix Therapeutics (PTX). The sale price on the business is $100 million, with an added $283.5 million … Read more